Status:
UNKNOWN
Response to CFTR Modulators in CF Patients Under 18 Years
Lead Sponsor:
Societe Francaise de la Mucoviscidose
Conditions:
Cystic Fibrosis in Children
Eligibility:
All Genders
Up to 18 years
Brief Summary
CFTR modulators should improve the prognosis of Cystic Fibrosis. Identifying patients under the age of 18 responding to CFTR modulators as well as detecting possible toxicity is an important medical o...
Detailed Description
Cystic fibrosis (CF) is a deadly disease. This is due to overinfected chronic obstructive pulmonary disease that progresses to end-stage respiratory failure. CFTR modulators should improve the prognos...
Eligibility Criteria
Inclusion
- Children with cystic fibrosis under the age of 18 under CFTR modulator therapy
Exclusion
- Patients with cystic fibrosis without indication for CFTR modulator therapy
- Patients over the age of 18
- Pregnant or lactating women
Key Trial Info
Start Date :
January 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2026
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT04301856
Start Date
January 1 2020
End Date
January 1 2026
Last Update
March 22 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sermet-Gaudelus Isabelle
Paris, France, 75015